Sequenom’s Petition for En Banc Rehearing Garners Broad Amicus Support
Read The Recorder's “Worried Biotech Advocates Swarm to Prenatal Testing Fight”On August 27, twelve amicus briefs were submitted to the Federal Circuit in support of Sequenom’s petition for an en banc rehearing of the panel decision in Ariosa v. Sequenom. The amici include BIO, the Bioindustry Association, Coalition for 21st Century Medicine, IPO, ILPA, Novartis, and two groups of prominent patent law academics -- a who’s who of biotech industry interests, patent owners’ organizations, and academics who have written extensively in this area of the law.
The case garnered unusually broad amicus support for good reason:
Read the recent IPWatchdog interview with Sequenom counsel Tom Goldstein, co-founder of the SCOTUS blogthe legal issues in this patent appeal will affect individuals across the country. The stakes here are extraordinarily high, with this controversial decision likely to significantly impact the speed of medical innovation, investment in cutting-edge diagnostics, and, most importantly, healthcare opportunities for pregnant women and their children.
The amici included:
|
Amicus |
Brief |
|
Biotechnology Industry Association (BIO) |
|
|
The Bioindustry Association (BIA) |
|
|
Coalition for 21st Century Medicine |
|
|
Jeffrey A. Lefstin and Peter S. Menell |
|
|
Twenty-Three Law Professors |
|
|
Intellectual Property Owners Association (IPO) |
|
|
Novartis AG |
|
|
New York Intellectual Property Law Association (NYIPLA) |
|
|
Paul Gilbert Cole |
|
|
Wisconsin Alumni Research Foundation (WARF) and The Marshfield Clinic |
|
|
Jyant Technologies Inc. |
|
|
Amarantus Bioscience Holdings, Inc., Personalis, Inc., and Population Diagnostics, Inc. |